JNJ vs PLX

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Protalix (PLX) maintains significant growth potential following the EU approval of Elfabrio's expanded dosing regimen and the triggered $25.0 million milestone, boosting projected cash to ~$50 million by April 2026. This, coupled with robust 2026 revenue guidance of $78–$83 million, strengthens its strategic market position in rare diseases. However, the FY 2025 TTM net loss of $6.6 million, a cle...